INT278362

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 13
Disease Relevance 15.71
Pain Relevance 4.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

pigmentation (Hps5) cytoplasm (Hps5)
Hps5 (Mus musculus)
Pain Link Frequency Relevance Heat
postherpetic neuralgia 312 99.92 Very High Very High Very High
Pain 228 99.04 Very High Very High Very High
Lasting pain 36 94.08 High High
Shingles 12 82.48 Quite High
Acute pain 12 77.64 Quite High
depression 12 45.84 Quite Low
cytokine 10 5.00 Very Low Very Low Very Low
Inflammation 8 5.00 Very Low Very Low Very Low
Inflammatory response 4 5.00 Very Low Very Low Very Low
chemokine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Herpes Zoster 1824 100.00 Very High Very High Very High
Post Operative Pain 312 99.92 Very High Very High Very High
Disease 270 99.52 Very High Very High Very High
Pain 228 99.04 Very High Very High Very High
Chickenpox 24 94.60 High High
Death 61 93.36 High High
Sprains And Strains 49 91.20 High High
Influenza Virus Infection 168 89.72 High High
Exanthema 72 89.40 High High
Immunization 36 84.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The ROS scavenger, N-acetylcysteine (NAC) inhibited both Hz- and MSU-induced IL-1?
Negative_regulation (inhibited) of Hz
1) Confidence 0.21 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2722371 Disease Relevance 0 Pain Relevance 0
In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.
Negative_regulation (reduction) of HZ associated with herpes zoster
2) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.10 Pain Relevance 0.44
In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.
Negative_regulation (reduction) of HZ associated with herpes zoster
3) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.06 Pain Relevance 0.38
The vaccine has been registered in the EU as a single dose vaccine for the prevention of HZ and PHN among people aged 50 years or older.


Negative_regulation (prevention) of HZ associated with herpes zoster and postherpetic neuralgia
4) Confidence 0.04 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.52 Pain Relevance 0.31
In the scenario with reduction of HZ cases only the cost-effectiveness ratio increases towards ~€33500 at the age of 70; using the scenario with reduction of PHN improves the cost-effectiveness to a ratio of ~€10000.
Negative_regulation (reduction) of HZ associated with herpes zoster and postherpetic neuralgia
5) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.41 Pain Relevance 0.17
Presently, a vaccine to prevent HZ is available [2].
Negative_regulation (prevent) of HZ associated with herpes zoster
6) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.30 Pain Relevance 0.41
Although the clinical trial showed a higher impact of vaccination on the BOI compared to the incidence of HZ, we want to mention that using BOI or PHN endpoints will be more sensitive towards the decisions made in the way the QALY loss due to HZ is currently modeled/estimated.
Negative_regulation (loss) of HZ associated with herpes zoster and postherpetic neuralgia
7) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.65 Pain Relevance 0.19
Only one vaccine (ZOSTAVAX®; SP-MSD) has been registered for the prevention of HZ.
Negative_regulation (prevention) of HZ associated with herpes zoster
8) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.21 Pain Relevance 0.36
In the scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY loss was included.
Negative_regulation (loss) of HZ associated with herpes zoster
9) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.06 Pain Relevance 0.39
There are no direct alternatives to prevent HZ.
Negative_regulation (prevent) of HZ associated with herpes zoster
10) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 2.52 Pain Relevance 0.70
The duration of pain by severity and age, and subsequently the QALY loss due to HZ, was estimated by Van Hoek et al [28] and applied to the Dutch situation.
Negative_regulation (loss) of HZ associated with pain and herpes zoster
11) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.28 Pain Relevance 0.62
In the scenario describing the reduction of BOI, a reduction of QALY loss for the first 6 months in people with disease was included above the reduction in HZ cases (this is because the vaccine reduces disease severity in cases where HZ occurs in spite of vaccination).
Negative_regulation (reduction) of HZ associated with herpes zoster and disease
12) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 1.10 Pain Relevance 0.39
Vaccine effectiveness, reflected by the reduction of the incidence of HZ, PHN and related hospitalizations, could be monitored using GP and hospitalization statistics.


Negative_regulation (reduction) of HZ associated with herpes zoster and postherpetic neuralgia
13) Confidence 0.03 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2928772 Disease Relevance 0.50 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox